FWM
ITRM

Focused Wealth Management’s Iterum Therapeutics ITRM Stock Holding History

Focused Wealth Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,666
Closed -$6.67K – 1095
2023
Q1 		$6.67K Sell
6,666
-333
-5% -$384 ﹤0.01% 614
2022
Q4 		$5.88K Hold
6,999
– – ﹤0.01% 616
2022
Q3 		$11K Sell
6,999
-1
-0% -$3 ﹤0.01% 477
2022
Q2 		$21K Buy
7,000
+333
+5% +$1.25K ﹤0.01% 400
2022
Q1 		$36K Hold
6,667
– – 0.01% 347
2021
Q4 		$39K Hold
6,667
– – 0.01% 401
2021
Q3 		$56K Hold
6,667
– – 0.01% 369
2021
Q2 		$231K Buy
6,667
+1,667
+33% +$36.1K 0.04% 156
2021
Q1 		$106K Hold
5,000
– – 0.02% 271
2020
Q4 		$74K Buy
+5,000
New +$58.5K 0.01% 303

Other funds holding ITRM

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
KFS
Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

Focused Wealth Management's ITRM Position: Q2 2023 in Review

Focused Wealth Management sold out of Iterum Therapeutics (ITRM) in Q2 2023, closing a stake of 6,666 shares — an estimated $6.67K sold.

Focused Wealth Management first reported a position in ITRM in Q4 2020 and held it in 10 quarters. The position peaked at $231K in Q2 2021. 17 funds tracked by Wall St. Rank hold ITRM as of Q2 2023.

  • Focused Wealth Management reported no remaining Iterum Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Focused Wealth Management sold 6,666 Iterum Therapeutics shares in Q2 2023, an estimated $6.67K.
  • Focused Wealth Management first reported a position in Iterum Therapeutics in Q4 2020 and held it in 10 quarters.
  • Focused Wealth Management's Iterum Therapeutics position peaked at $231K in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2023.

Based on Focused Wealth Management's 13F filing for Q2 2023, filed 8 Aug 2023.